BALANCE SHEETS AND DATA MEASURING CONSUMER SPENDING GUIDE THE MARKETS, WITH AN EYE ON THE GEOPOLITICAL CONFLICT; EUROPEAN STOCKS AND US INDEX FUTURES RISE Markets on Wednesday continued to be guided by the crop of balance sheets, today with companies of the stature of Meta, and indicators that give clues about the resistance of economies to soaring inflation and constant threats to the supply...
Continue reading >>
MUSK’S ACQUISITION OF TWITTER COMPLICATES THE POSSIBLE MERGER OF DWAC WITH TRUTH SOCIAL. Digital World Acquisition Corp jumped 25.14% on Tuesday following the announcement that Elon Musk had acquired Twitter for 44 billion. The Special purpose acquisition firm is planning to merge with ex-US President Donald Trump’s social media platform. Following the announcement that Trump’s Truth...
Continue reading >>
In Europe, stocks have been positive since opening; S&P and Dow futures struggle to stay positive, but Nasdaq contracts surrender to Netflix crash North American markets, whose tone had deteriorated since yesterday’s close, are struggling to position themselves in the positive field. But the results of Netflix, whose shares fell as much as 27% before the stock market opened, cooled the...
Continue reading >>
CHECKMATE UP 329% FOLLOWING ACQUISITION PROPOSAL Checkmate Pharmaceuticals (NASDAQ: CMPI) shares were up 329% in response to a $250 million buyout proposal from Regeneron Pharmaceuticals (NASDAQ: REGN). Regeneron is looking to acquire Checkmate in an all-cash deal of $10.5 per share, representing a 332% premium from where Checkmate Pharmaceuticals’ shares closed on Monday. The companies...
Continue reading >>
US AND EUROPEAN MARKETS REBOUND FOLLOWING ROUGH PATCH Global markets are dealing with a series of challenges. Escalating war in Ukraine, balance sheet season, and macroeconomic indicators, especially inflation. However, following three consecutive red days on Wall Street, bargain hunters may be tempted to take action. US index futures are gaining traction, with mining and energy companies...
Continue reading >>
C4 THERAPEUTICS ANNOUNCES CFT7445 STUDY RESULTS C4 Therapeutics Inc. (NASDAQ: CCCC) dropped 50.57% after announcing Cohort A from the ongoing Phase 1/2 clinical study of CFT7455, a proprietary degrader that targets IKZF1/3 for non-Hodgkin’s lymphomas and multiple myeloma. The company has learned a lot from only five melanoma patients in the study’s first cohort. Now, C4 Therapeutics Knows...
Continue reading >>